New drug SIM0505 enters first human tests for advanced cancers

NCT ID NCT06792552

Recruiting now Disease control Sponsor: NextCure, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will receive the drug by injection every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIM0505 (an experimental drug given by injection)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and the main goal is to find a safe dose, not to prove it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma fallopian tube cancer fallopian tube neoplasm lung adenocarcinoma neoplasm non-small cell lung carcinoma nonpapillary renal cell carcinoma ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma papillary renal cell carcinoma primary peritoneal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS FALLOPIAN TUBE CANCER NSCLC (NON-SMALL CELL LUNG CANCER) PAPILLARY RENAL CELL CARCINOMA (PRCC) PLATINUM-RESISTANT OVARIAN CANCER PRIMARY PERITONEAL CANCER RENAL CELL CARCINOMA (RCC) UTERINE SEROUS CARCINOMA (USC)

Contacts and locations

Locations

Affiliated Hospital of Jining Medical University
RECRUITING

Jining, Shandong, 272000, China
Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, 250117, China
Dana-Farber Cancer Institute
ACTIVE_NOT_RECRUITING

Boston, Massachusetts, 02215, United States
Emory Winship Cancer Institute
ACTIVE_NOT_RECRUITING

Atlanta, Georgia, 30322, United States
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Hackensack University Medical Center
ACTIVE_NOT_RECRUITING

Hackensack, New Jersey, 07601, United States
HunanCancer Hospital
RECRUITING

Changsha, Hunan, 430100, China
Icahn School of Medicine at Mount Sinai
ACTIVE_NOT_RECRUITING

New York, New York, 10128, United States
Liaoning Cancer Hospital & Institute
NOT_YET_RECRUITING

Shenyang, China, 110092, China
Roswell Park Cancer Institute
ACTIVE_NOT_RECRUITING

Buffalo, New York, 14263, United States
Sarah Cannon Research Institute (SCRI) - Lake Nona
ACTIVE_NOT_RECRUITING

Orlando, Florida, 32827, United States
Sarah Cannon Research Institute (SCRI) - Nashville
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37203, United States
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The Fourth Hospital of Hebei Medical University (Heibei Tumor Hospital)
NOT_YET_RECRUITING

Shijiazhuang, China, 050010, China
The first medical center of PLA general hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China
UT Health San Antonio - Mays Cancer Center
ACTIVE_NOT_RECRUITING

San Antonio, Texas, 78229, United States
University Medical Center of New Orleans LSU-LCMC Health Cancer Center
ACTIVE_NOT_RECRUITING

New Orleans, Louisiana, 70112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.